Oxaliplatin-induced peripheral neuropathy with hepatic arterial versus intravenous infusion in metastatic colorectal cancer

被引:1
|
作者
Valery, Marine [1 ]
Tanguy, Marie-Laure [2 ,3 ]
Gelli, Maximiliano [4 ]
Smolenschi, Cristina [1 ,5 ]
Hollebecque, Antoine [1 ,5 ]
Boileve, Alice [1 ,6 ]
de Sevilla, Elena Fernandez [4 ]
Tselikas, Lambros [7 ]
Bonnet, Baptiste [7 ]
Goere, Diane [8 ]
Taieb, Julien [9 ]
Boige, Valerie [1 ]
Ducreux, Michel [1 ,6 ]
Malka, David [6 ,10 ]
机构
[1] Univ Paris Saclay, Dept Med Oncol, Gustave Roussy, F-94805 Villejuif, France
[2] Univ Paris Saclay, Serv Biostat & Epidemiol, Gustave Roussy, F-94805 Villejuif, France
[3] Univ Paris Saclay, Equipe Labellisee Ligue Contre Le Canc, INSERM, Oncostat U1018, Villejuif, France
[4] Univ Paris Saclay, Dept Chirurg Oncol, Gustave Roussy, F-94805 Villejuif, France
[5] Univ Paris Saclay, Dept Innovat Therapeut, Gustave Roussy, F-94805 Villejuif, France
[6] Univ Paris Saclay, INSERM, Unite Dynam Cellules Tumorales, Gustave Roussy, F-94805 Villejuif, France
[7] Univ Paris Saclay, Dept Imagerie Med & Radiol Intervent, Gustave Roussy, F-94805 Villejuif, France
[8] Hop Univ St Louis, Serv Chirurg Viscerale Cancerol & Endocrinienne, Paris, France
[9] Hop Europeen Georges Pompidou, Serv Oncol Digest, Paris, France
[10] Inst Mutualiste Montsouris, Dept Oncol Med, 42 Blvd Jourdan, F-75014 Paris, France
关键词
Neuropathy; Oxaliplatin; Hepatic arterial infusion chemotherapy; Metastatic colorectal cancer; QUALITY-OF-LIFE; III COLON-CANCER; LIVER METASTASES; COMBINATION CHEMOTHERAPY; REDUCED GLUTATHIONE; DOUBLE-BLIND; OPEN-LABEL; PHASE-II; CETUXIMAB; TRIAL;
D O I
10.1007/s00520-024-08807-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundOxaliplatin, a major drug in metastatic colorectal cancer (mCRC), is responsible for cumulative, dose-limiting peripheral neuropathy (PN). Whether the hepatic arterial infusion (HAI) route can limit oxaliplatin-induced PN in comparison with the intravenous (IV) route has not been specifically explored so far.MethodsWe compared the frequency and severity of PN in oxaliplatin-naive patients with mCRC included in trials that evaluated treatment with oxaliplatin administered either by HAI (ACCORD 04, CHOICE, OSCAR, and PACHA-01 trials) or by IV route (FFCD 2000-05 trial). We retrieved anonymized, prospectively collected data from trial databases for the ACCORD 04, CHOICE, and FFCD 2000-05 trials and through a review of Gustave Roussy patients' electronic medical records for PACHA-01 and OSCAR trials.The primary endpoint was the incidence of clinically significant PN (grades 2 to 4) according to the cumulative dose of oxaliplatin received. Secondary endpoints were time to onset of neuropathy as a function of the cumulative dose of oxaliplatin, discontinuation of oxaliplatin for neurotoxicity, and safety.MethodsWe compared the frequency and severity of PN in oxaliplatin-naive patients with mCRC included in trials that evaluated treatment with oxaliplatin administered either by HAI (ACCORD 04, CHOICE, OSCAR, and PACHA-01 trials) or by IV route (FFCD 2000-05 trial). We retrieved anonymized, prospectively collected data from trial databases for the ACCORD 04, CHOICE, and FFCD 2000-05 trials and through a review of Gustave Roussy patients' electronic medical records for PACHA-01 and OSCAR trials.The primary endpoint was the incidence of clinically significant PN (grades 2 to 4) according to the cumulative dose of oxaliplatin received. Secondary endpoints were time to onset of neuropathy as a function of the cumulative dose of oxaliplatin, discontinuation of oxaliplatin for neurotoxicity, and safety.ResultsA total of 363 patients were included (IV, 300; HAI, 63). In total, 180 patients in the IV group (60%) and 30 patients in the HAI group (48%) developed clinically significant PN, with no significant difference between the two groups (p = 0.23). No difference was shown in the time to onset of PN either (p = 0.23).ConclusionThe administration of oxaliplatin HAI rather than IV in the treatment of mCRC does not reduce the incidence, precocity, and severity of PN.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Calcium/Magnesium Infusion for Oxaliplatin-Induced Neuropathy: Protective or Not?
    Avan, Abolfazl
    Avan, Amir
    Giovannetti, Elisa
    Peters, Godefridus J.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (29) : 3341 - 3341
  • [22] Oxaliplatin-Induced Neuropathy in Colorectal Cancer: Many Questions With Few Answers
    Zedan, Ahmed Hussein
    Hansen, Torben Frostrup
    Svenningsen, Asa Fex
    Vilholm, Ole Jakob
    CLINICAL COLORECTAL CANCER, 2014, 13 (02) : 73 - 80
  • [23] The role of reduced glutathione on oxaliplatin-induced neuropathy in colorectal cancer patients
    Lelli, G.
    Romano, G.
    Ardito, R.
    Bochicchio, A.
    Capobianco, A.
    Coccaro, M.
    Di Leo, P.
    Tartarone, A.
    Romano, C.
    Calvi, N.
    Lorusso, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [24] Effect of reduced glutathione on oxaliplatin-induced neuropathy in colorectal cancer patients
    Giampiero, R.
    Raffaele, A.
    Annamaria, B.
    Alba, C.
    Mariarosa, C.
    Pasquale, D. L.
    Alfredo, T.
    ANNALS OF ONCOLOGY, 2006, 17 : XI66 - XI66
  • [25] Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients
    Velasco, Roser
    Bruna, Jordi
    Briani, Chiara
    Argyriou, Andreas A.
    Cavaletti, Guido
    Alberti, Paola
    Frigeni, Barbara
    Cacciavillani, Mario
    Lonardi, Sara
    Cortinovis, Diego
    Cazzaniga, Marina
    Santos, Cristina
    Kalofonos, Haralabos P.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2014, 85 (04): : 392 - 398
  • [26] Treatment of oxaliplatin-induced peripheral neuropathy with oxycodone and extension of FOLFOX in patients with advanced colorectal cancer.
    Nagashima, M.
    Ooshiro, M.
    Kitahara, T.
    Takagi, R.
    Moriyama, A.
    Urita, T.
    Yoshida, Y.
    Tanaka, H.
    Oshiro, T.
    Okazumi, S.
    Katoh, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [27] Hepatic arterial infusion of chemotherapy for metastatic colorectal cancer
    Atkins, CD
    NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (20): : 1524 - 1525
  • [28] Subjective and objective assessment of oxaliplatin-induced peripheral neuropathy
    Matsuoka, Taisuke
    Yoshida, Yoichiro
    Mogi, Ai
    Yamada, Teppei
    Aisu, Naoya
    Kojima, Daibo
    Tanimura, Syu
    Koganemaru, Tomoko
    Kiyomi, Fumiaki
    Yamashita, Yuichi
    ANNALS OF ONCOLOGY, 2015, 26 : 114 - 114
  • [29] Neurotropin ameliorates oxaliplatin-induced peripheral neuropathy in rats
    Kawashiri, Takehiro
    Egashira, Nobuaki
    Watanabe, Hitomi
    Hirakawa, Shingo
    Ikegami, Yoko
    Yano, Takahisa
    Ikesue, Hiroaki
    Oishi, Ryozo
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2010, 112 : 218P - 218P
  • [30] Lack of oxaliplatin dose adjustment is correlated with an increased frequency of oxaliplatin-induced neuropathy in obese patients with metastatic colorectal cancer (mCRC)
    Stocker, G.
    Giessen-Jung, C.
    Schmiegel, W.
    Lordick, F.
    Hacker, U.
    Heinemann, V
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 198 - 198